Navigation Links
RECITAL Study Presents Excellent Outcomes and Rapid Patient Recovery With Revolutionary Femoral Access Procedure
Date:12/1/2011

REDWOOD CITY, Calif., Dec. 1, 2011 /PRNewswire/ -- Clinical Investigators for Arstasis, Inc., reported the results of the RECITAL study during the recent TCT Meeting in San Francisco, demonstrating the Arstasis access device enables rapid, secure, implant-free closure of femoral arteries after cardiac catheterization procedures. The device creates a unique access pathway, called an Arstaotomy, into the femoral artery through which catheterization procedures are performed.

RECITAL is a prospective, multi-center clinical study that enrolled 351 patients to assess device and procedural success of key post-catheterization recovery measures that influence the safety and speed toward discharging those patients from the hospital. The results indicate that hospitals may be able to both reduce current complication rates and eliminate costs from longer hospitalizations in this patient population.

Key results of the RECITAL study showed that device deployment was successful in 97% of RECITAL patients and femoral bleeding stopped after only 3 minutes for diagnostic angiogram patients and 5 minutes for anti-coagulated patients undergoing a percutaneous coronary intervention (PCI). Most of the patients were able to sit up within 15-30 minutes and were able to walk in about one hour after an angiogram and two hours after a PCI. Investigators found no major complications related to use of the Arstasis device.

Dr. Dale Wortham, University of Tennessee  Medical Center, Knoxville and RECITAL Study Principal Investigator, commented, "Introducing foreign materials in a patient to close the femoral artery can be problematic. We were very pleased the RECITAL Study demonstrated the Arstaotomy procedure can deliver closure-like hemostasis and ambulation times without the use of a temporary or permanent implant."

The RECITAL Study illustrates the Arstaotomy procedure can potentially accelerate patient throughput, delivering a quicker, m
'/>"/>

SOURCE Arstasis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Announces First Patient Dosed in XIAFLEX® Study for Frozen Shoulder Syndrome
2. Ceregene Completes Enrollment of Second Phase 2 Study of CERE-120 for the Treatment of Parkinsons Disease
3. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Combination Study of MM-121 and Multiple Anticancer Therapies in Patients with Advanced Solid Tumors
4. BioMarin Initiates Phase 2 Study for GALNS in Patients Under Five Years of Age With MPS IVA
5. New Study Points to Novel Mechanism by Which Tumors Escape Recognition by the Immune System
6. Inspiration Biopharmaceuticals Initiates Second Pivotal Clinical Study of Innovative Hemophilia Therapy OBI-1
7. Cara Therapeutics Initiates Phase I Study with Oral Formulation of Novel Peripherally-Acting Kappa Opioid Agonist
8. Updated Survival Data from Study Comparing TTF™ (Tumor Treating Fields) Therapy to Best Standard Chemotherapy for Recurrent Glioblastoma Reported at the 16th Annual Scientific Meeting of the Society for NeuroOncology
9. Perceptive Informatics® Global Survey Results Indicate Wide Use of Industry-Standard Medical Imaging Metrics to Meet Study Milestones
10. Merrimack Pharmaceuticals Initiates Enrollment in Phase 2 Study of MM-121 in Combination with Erlotinib in Three Groups of Patients with Non-Small Cell Lung Cancer
11. goBalto Sponsors Tufts CSDD Study to Benchmark the Clinical Trial Initiation Process
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... WASHINGTON , July 31, 2014  According to ... Medicaid Services, the 2015 average monthly Medicare Part D ... figure far lower than was originally projected, the Pharmaceutical ... Part D program continues to be a bright spot ... competing choices in each region and using cutting edge, ...
(Date:7/31/2014)... July 31, 2014  Sorrento Therapeutics, Inc. (NASDAQ: ... Amar Singh , Chief Business Officer and Executive Vice President. ... on July 30. "Sorrento is deeply saddened and ... Our immediate thoughts go to Amar,s family and friends," said ... Officer. Mr. Singh joined Sorrento in January ...
(Date:7/31/2014)... MONROVIA, Calif., July 31, 2014 STAAR Surgical ... manufacturer and marketer of implantable lenses and delivery systems ... quarter ended July 4, 2014 of $20.0 million, a ... quarter of 2013. On a constant currency basis, revenues ... to the second quarter of 2013.  The effect of ...
Breaking Medicine Technology:Sorrento Announces the Unexpected Death of its Chief Business Officer 2STAAR Surgical Reports 10% Second Quarter Revenue Growth 2STAAR Surgical Reports 10% Second Quarter Revenue Growth 3STAAR Surgical Reports 10% Second Quarter Revenue Growth 4STAAR Surgical Reports 10% Second Quarter Revenue Growth 5STAAR Surgical Reports 10% Second Quarter Revenue Growth 6STAAR Surgical Reports 10% Second Quarter Revenue Growth 7STAAR Surgical Reports 10% Second Quarter Revenue Growth 8STAAR Surgical Reports 10% Second Quarter Revenue Growth 9STAAR Surgical Reports 10% Second Quarter Revenue Growth 10STAAR Surgical Reports 10% Second Quarter Revenue Growth 11STAAR Surgical Reports 10% Second Quarter Revenue Growth 12STAAR Surgical Reports 10% Second Quarter Revenue Growth 13STAAR Surgical Reports 10% Second Quarter Revenue Growth 14STAAR Surgical Reports 10% Second Quarter Revenue Growth 15STAAR Surgical Reports 10% Second Quarter Revenue Growth 16STAAR Surgical Reports 10% Second Quarter Revenue Growth 17STAAR Surgical Reports 10% Second Quarter Revenue Growth 18STAAR Surgical Reports 10% Second Quarter Revenue Growth 19STAAR Surgical Reports 10% Second Quarter Revenue Growth 20STAAR Surgical Reports 10% Second Quarter Revenue Growth 21STAAR Surgical Reports 10% Second Quarter Revenue Growth 22STAAR Surgical Reports 10% Second Quarter Revenue Growth 23STAAR Surgical Reports 10% Second Quarter Revenue Growth 24STAAR Surgical Reports 10% Second Quarter Revenue Growth 25STAAR Surgical Reports 10% Second Quarter Revenue Growth 26STAAR Surgical Reports 10% Second Quarter Revenue Growth 27STAAR Surgical Reports 10% Second Quarter Revenue Growth 28STAAR Surgical Reports 10% Second Quarter Revenue Growth 29STAAR Surgical Reports 10% Second Quarter Revenue Growth 30STAAR Surgical Reports 10% Second Quarter Revenue Growth 31
... 2007,/PRNewswire-FirstCall/ -- Cell Genesys, Inc. today announced,follow-up ... of GVAX immunotherapy,for pancreatic cancer which was ... Center. The trial enrolled 60 patients with,operable ... of their tumor and adjuvant radiation and,chemotherapy. ...
... 2002 , CHICAGO/DARMSTADT, Germany, June 4, 2007 – ... the American Society of,Clinical Oncology (ASCO) annual meeting ... patients with newly diagnosed,glioblastoma – a particularly aggressive ... integrin inhibitor targeting the,tumor and its vasculature. , ...
Cached Medicine Technology:Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of,GVAX Immunotherapy for Pancreatic Cancer 2Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of,GVAX Immunotherapy for Pancreatic Cancer 3Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of,GVAX Immunotherapy for Pancreatic Cancer 4Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of,GVAX Immunotherapy for Pancreatic Cancer 5Merck at ASCO 2007: Encouraging Results in Progression-Free,Survival in Patients With Aggressive Brain Tumors (glioblastoma),Using Cilengitide in Phase I/IIa Study 2Merck at ASCO 2007: Encouraging Results in Progression-Free,Survival in Patients With Aggressive Brain Tumors (glioblastoma),Using Cilengitide in Phase I/IIa Study 3Merck at ASCO 2007: Encouraging Results in Progression-Free,Survival in Patients With Aggressive Brain Tumors (glioblastoma),Using Cilengitide in Phase I/IIa Study 4Merck at ASCO 2007: Encouraging Results in Progression-Free,Survival in Patients With Aggressive Brain Tumors (glioblastoma),Using Cilengitide in Phase I/IIa Study 5
(Date:7/31/2014)... 2014 Cosmetic Town has introduced a ... doctors. Doctors will be able to verify their patients ... , which guarantees their authenticity. This will help ... to receive information that has been verified to come ... allows Cosmetic Town to filter out fake patients who ...
(Date:7/31/2014)... United Theological Seminary is pleased to ... Donne and Peter J. Bellini. Both began their teaching ... is a Director of Non-Degree Programs, Mark Abbott, who ... Le Donne, Assistant Professor of New Testament, received a ... Testament, Second Temple Judaism, and Greek courses. His research ...
(Date:7/31/2014)... 2014 Jeremiah’s Tavern ... wood to create a unique atmosphere and highlight ... features reclaimed barn siding on the ... mixed softwoods flowing throughout the interior as flooring. ... sister company New Energy Works Timberframers ...
(Date:7/31/2014)... July 31, 2014 NEWwoodworks, fine woodworking ... expanding their brand presence with a website dedicated to ... years, NEWwoodworks has specialized in handcrafted cabinetry, furniture, ... NEWwoodworks has earned a reputation for taking on the ... on. They commonly craft with reclaimed wood, often using ...
(Date:7/31/2014)... Los Angeles, CA (PRWEB) July 31, 2014 ... connects Southern California’s best Plastic Surgeons to consumers considering ... been recommended by their peers whose goal is to ... The doctors are selected through a validated referral ... area who are the best in their respective fields. ...
Breaking Medicine News(10 mins):Health News:Cosmetic Town Improves Patient Experience Through Secure Verification of Patients and Doctors 2Health News:Growing Seminary Welcomes New Faculty 2Health News:Popular Tavern Restaurant Features Pioneer Millworks’ Reclaimed Wood in New Locations 2Health News:NEWwoodworks Fine Woodworking Group Launches New Website 2Health News:NEWwoodworks Fine Woodworking Group Launches New Website 3Health News:The New Doctors’ Directory, Cosmetic Town Does the Research for Consumers of Plastic Surgeries 2
... resident Daniel Alford, MD, an associate professor of medicine ... in the General Internal Medicine Department at Boston Medical ... Abuse Prevention and Treatment Division with the Boston Public ... nation to receive the Nyswander-Dole Award. The award was ...
... ViroPharma Incorporated,(Nasdaq: VPHM ) reported today its financial results for ... since June 30, 2007 include:, Clinical:, -- Patient enrollment ... in liver transplant patients; -- Patient enrollment continued ... stem cell transplant patients; study enrollment expanded to ...
... Inc.,(Pink Sheets: HRAL) announced that it has received additional ... International, Inc.,(NYSE: WMT ), to open their ninth ... Wal-Mart Store #3195 located at 1070 Major,Mackenzie Drive in ... #7 Unit Y006A in Markham will both officially open ...
... Revenue and EPS Guidance; Provides Preliminary ... 2008 Guidance ... AM ET, BATON ROUGE, La., Oct 30 Amedisys, Inc.,(Nasdaq: AMED ... reported its financial results for the,third quarter ended September 30, 2007: Three-Month ...
... FREISING-WEIHENSTEPHAN, Germany, October 30 Pieris ... Netherlands) today,announced the commencement of a ... for G-Protein Coupled Receptors (GPCRs) and ... has pioneered Anticalins(R) as next generation ...
... Inc. (NYSE: CRY ),a biomaterials, medical device and ... been named vice president, clinical research,effective October 29, 2007. ... of CryoLife Europa, Ltd., based in the U.K., since ... has held several positions with,the Company including project director ...
Cached Medicine News:Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 2Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 3Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 4Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 5Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 6Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 7Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 8Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 9Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 10Health News:HearAtLast Continues Rapid Expansion, Opening Two New Retail Locations in Richmond Hill and Markham Wal-Mart Stores Number 3195 and 3053 2Health News:HearAtLast Continues Rapid Expansion, Opening Two New Retail Locations in Richmond Hill and Markham Wal-Mart Stores Number 3195 and 3053 3Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 2Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 3Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 4Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 5Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 6Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 7Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 8Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 9Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 10Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 11Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 12Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 13Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 14Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 15Health News:Pieris and Pepscan to Identify GPCR-Specific Anticalins(R) Using CLIPS(TM) Protein Mimicry Technology 2Health News:Pieris and Pepscan to Identify GPCR-Specific Anticalins(R) Using CLIPS(TM) Protein Mimicry Technology 3Health News:CryoLife Announces Additions to Management Team 2
... The TheraSeed® Pd-103 implant is a ... and remarkable visibility that makes TheraSeed® treatment ... You can be confident that every TheraSeed® ... management services which is required by clinicians ...
... BrachyStar® Needle is designed to help you ... clinically effective brachytherapy procedure. All needles are ... and polished surfaces for smooth entry and ... and sizes assures an ideal match with ...
... is a combination of innovative design, consistently ... BrachySource I-125 implant an ideal choice for ... that every BrachySource I-125 implant order is ... is required by clinicians who must meet ...
... temporary internal drainage from the ureteropelvic junction ... stricture. The segment with no sideports prevents ... preventing ingrowth of the ureteral wall to ... Intended for one-time use. CAUTION: Periodic evaluation ...
Medicine Products: